Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of a personalized cancer vaccine alone and in combination with toripalimab in patients with resected NSCLC. The study included dose escalation and dose expansion two parts.

NCT Number	NCT07683832
Lead Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Collaborators: Suzhou Abogen Biosciences Co., Ltd.
Conditions	Non-Small Cell Lung Cancer NSCLC
Enrollment	50 participants
Start Date	2026-07-28
Primary Completion	2028-12-31 (estimated)
Study Completion	2031-04-17 (estimated)
Updated on ClinicalTrials.gov	2026-07-06